Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.